Tata Sons-backed biotech startup MedTherapy said it has developed a next-generation CAR-T cell therapy manufacturing platform that can redu...

India’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...

India is taking a groundbreaking step forward in the realm of rare disease care with a distinctive approach that champions local ingenuity ...

Gilead will pay $115 per share in cash at the deal's closing, which is at a premium of 79% to the stock's last close. Kite Pharma, a unit ?...

This therapy targets multiple tumor-specific antigens, offering improved treatment precision for blood cancer patients, and significantly r...

Researchers, including those from the Indian Institute of Technology-Bombay and Tata Memorial Hospital, Mumbai, said in low and middle-inco...

Immuneel Therapeutics, co-founded by Kiran Mazumdar-Shaw, has introduced Qartemi, India's second CAR-T cell therapy, to treat B-cell Non-Ho...

India has reached a milestone in cancer treatment with the first successful allogeneic CAR-T therapy at P. D. Hinduja Hospital, led by Dr. ...

Aurigene Oncology has announced promising phase-1 results for its novel CAR-T cell therapy, Ribrecabtagene autoleucel, in patients with mul...

Indian company ImmunoACT, backed by drug maker Laurus Labs, has received approval from the Central Drugs Standard Control Organization for ...

The fresh infusion of capital will enable ImmunoACT to fast-track the scale-up of its lead candidate HCAR-19 by expansion of the multi-loca...

The early results from the IMAGINE study were based on the first 10 patients of the planned 24 patients to be enrolled.Both adult and child...

CAR T Cell therapy involves genetically engineering T cells, white blood cells to fight cancer.

"Chimeric Antigen Receptor cells represent a cutting-edge technology that holds great promise for cancer treatment. We are delighted to off...

Founded in 2018 by Dr Rahul Purwar and a team of scientists, ImmunoACT is collaborating with institutions like Tata Memorial Hospital. Carl...

As per the agreement, Laurus will acquire 26.62% stake (fully diluted basis) for a cash consideration of approximately Rs 46 crores, subjec...

The collaboration opens up opportunities for co-development of advanced assets to be deployed in Spain and India, said Immuneel in a press ...